BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 9339690)

  • 1. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
    Guttman M
    Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
    Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
    J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
    Shannon KM; Bennett JP; Friedman JH
    Neurology; 1997 Sep; 49(3):724-8. PubMed ID: 9305331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O; Gasser T; van Hilten JJ; Spieker S; Pollentier S; Meier D; Oertel WH
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study.
    Lieberman A; Ranhosky A; Korts D
    Neurology; 1997 Jul; 49(1):162-8. PubMed ID: 9222185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
    Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.